Effect of Fosinopril Treatment on Serum C-Reactive Protein Levels in Patients With Microalbuminuria

American Journal of Cardiology

Volumn 102, Issue 2, 2008, Pages 223-225

  van der Harst, Pim ^a   Asselbergs, Folkert W ^a   Hillege, Hans L ^a   Voors, Adriaan A ^a   van Veldhuisen, Dirk J ^a   van Gilst, Wiek H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; FOSINOPRIL; PLACEBO; PRAVASTATIN; QUINAPRIL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE;

ALBUMINURIA; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; FOSINOPRIL; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; ODDS RATIO; RENIN-ANGIOTENSIN SYSTEM; SEX FACTORS;

EID: 46349098150     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.108     Document Type: Article

References (20)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E., and Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98 (1998) 839-844
3. van der Harst P., Voors A.A., Volbeda M., Buikema H., van Veldhuisen D.J., and van Gilst W.H. Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. Am J Cardiol 97 (2006) 1697-1701
4. Di N.M., and Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 34 (2003) 2922-2929
5. Takeda T., Hoshida S., Nishino M., Tanouchi J., Otsu K., and Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169 (2003) 155-158
6. Stenvinkel P., Andersson P., Wang T., Lindholm B., Bergstrom J., Palmblad J., Heimburger O., and Cederholm T. Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?. J Intern Med 246 (1999) 503-507
7. Tikiz C., Utuk O., Pirildar T., Bayturan O., Bayindir P., Taneli F., Tikiz H., and Tuzun C. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 32 (2005) 2095-2101
8. Schieffer B., Bunte C., Witte J., Hoeper K., Boger R.H., Schwedhelm E., and Drexler H. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44 (2004) 362-368
9. Asselbergs F.W., Diercks G.F., Hillege H.L., van Boven A.J., Janssen W.M., Voors A.A., de Zeeuw D., de Jong P.E., van Veldhuisen D.J., and van Gilst W.H. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 (2004) 2809-2816
10. van der Harst P., Asselbergs F.W., Hillege H.L., Bakker S.J., Voors A.A., van Veldhuisen D.J., and van Gilst W.H. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol. Am J Cardiol 100 (2007) 1548-1551
11. van der Harst P., Asselbergs F.W., Buikema H., Voors A.A., van Veldhuisen D.J., and van Gilst W.H. Effects of C-reactive protein and cholesterol on responsiveness in vitro of the internal thoracic artery to angiotensin II in patients having coronary artery bypass grafting. Am J Cardiol 98 (2006) 751-753
12. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., and Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
13. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 52 (2005) 20-28
14. Mora S., and Ridker P.M. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention?. Am J Cardiol 97 suppl (2006) 33A-41A
15. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24 (2006) 33-50
16. Asselbergs F.W., van der Harst P., Jessurun G.A., Tio R.A., and van Gilst W.H. Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. Vasc Pharmacol 42 (2005) 125-140
17. Koulouris S., Symeonides P., Triantafyllou K., Ioannidis G., Karabinos I., Katostaras T., El-Ali M., Theodoridis T., Vratsista E., Thalassinos N., et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 95 (2005) 1386-1388
18. Palmas W., Ma S., Psaty B., Goff Jr. D.C., Darwin C., and Barr R.G. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am J Hypertens 20 (2007) 233-241
19. van de Wal R.M., Gansevoort R.T., van der Harst P., Boomsma F., Thijs Plokker H.W., van Veldhuisen D.J., de Jong P.E., van Gilst W.H., and Voors A.A. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension 48 (2006) 870-876
20. Fliser D., Buchholz K., and Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107